120 related articles for article (PubMed ID: 1800459)
1. Optimal antibody-radionuclide combinations for clinical radioimmunotherapy: a predictive model based on mouse pharmacokinetics.
Yorke ED; Beaumier PL; Wessels BW; Fritzberg AR; Morgan AC
Int J Rad Appl Instrum B; 1991; 18(8):827-35. PubMed ID: 1800459
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the targeting characteristics of various radioimmunoconjugates for radioimmunotherapy of neuroblastoma: dosimetry calculations incorporating cross-organ beta doses.
Ugur O; Kostakoglu L; Hui ET; Fisher DR; Garmestani K; Gansow OA; Cheung NK; Larson SM
Nucl Med Biol; 1996 Jan; 23(1):1-8. PubMed ID: 9004907
[TBL] [Abstract][Full Text] [Related]
3. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments.
Casey JL; Pedley RB; King DJ; Green AJ; Yarranton GT; Begent RH
Br J Cancer; 1999 Nov; 81(6):972-80. PubMed ID: 10576653
[TBL] [Abstract][Full Text] [Related]
4. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
5. Comparative biodistribution and radioimmunotherapy of monoclonal antibody RS7 and its F(ab')2 in nude mice bearing human tumor xenografts.
Stein R; Blumenthal R; Sharkey RM; Goldenberg DM
Cancer; 1994 Feb; 73(3 Suppl):816-23. PubMed ID: 8306265
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical evaluation of a new murine monoclonal antibody (Mu-9) against colon-specific antigen-p for targeting gastrointestinal carcinomas.
Sharkey RM; Goldenberg DM; Vagg R; Pawlyk D; Wong GY; Siegel JA; Murthy S; Levine GM; Izon D; Gascon P
Cancer; 1994 Feb; 73(3 Suppl):864-77. PubMed ID: 8306272
[TBL] [Abstract][Full Text] [Related]
7. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry.
Behr TM; Sharkey RM; Sgouros G; Blumenthal RD; Dunn RM; Kolbert K; Griffiths GL; Siegel JA; Becker WS; Goldenberg DM
Cancer; 1997 Dec; 80(12 Suppl):2591-610. PubMed ID: 9406714
[TBL] [Abstract][Full Text] [Related]
8. Selection of radioimmunoconjugates for the therapy of well-established or micrometastatic colon carcinoma.
Sharkey RM; Blumenthal RD; Behr TM; Wong GY; Haywood L; Forman D; Griffiths GL; Goldenberg DM
Int J Cancer; 1997 Jul; 72(3):477-85. PubMed ID: 9247292
[TBL] [Abstract][Full Text] [Related]
9. Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments.
Casey JL; King DJ; Chaplin LC; Haines AM; Pedley RB; Mountain A; Yarranton GT; Begent RH
Br J Cancer; 1996 Nov; 74(9):1397-405. PubMed ID: 8912535
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies.
Brouwers A; Mulders P; Oosterwijk E; Buijs W; Corstens F; Boerman O; Oyen W
Cancer Biother Radiopharm; 2004 Aug; 19(4):466-77. PubMed ID: 15453961
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab')2 fragments in experimental ovarian cancer.
Molthoff CF; Pinedo HM; Schlüper HM; Nijman HW; Boven E
Br J Cancer; 1992 May; 65(5):677-83. PubMed ID: 1586596
[TBL] [Abstract][Full Text] [Related]
12. Potential and limitations of radioimmunodetection and radioimmunotherapy with monoclonal antibodies.
Zhu H; Baxter LT; Jain RK
J Nucl Med; 1997 May; 38(5):731-41. PubMed ID: 9170438
[TBL] [Abstract][Full Text] [Related]
13. Comparative evaluation of capsular polysaccharide-specific IgM and IgG antibodies and F(ab')2 and Fab fragments as delivery vehicles for radioimmunotherapy of fungal infection.
Dadachova E; Bryan RA; Huang X; Ortiz G; Moadel T; Casadevall A
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5629s-5635s. PubMed ID: 17875799
[TBL] [Abstract][Full Text] [Related]
14. The effect of radioimmunotherapy using murine monoclonal antibody KIS1 on esophageal squamous cell carcinoma-bearing nude mice.
Fujii T; Yamana H; Toh Y; Toh U; Fujita H; Shirouzu K; Morimatsu M
Surg Today; 1997; 27(11):1026-34. PubMed ID: 9413055
[TBL] [Abstract][Full Text] [Related]
15. Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose.
Elgqvist J; Andersson H; Bäck T; Claesson I; Hultborn R; Jensen H; Johansson BR; Lindegren S; Olsson M; Palm S; Warnhammar E; Jacobsson L
J Nucl Med; 2006 Aug; 47(8):1342-50. PubMed ID: 16883015
[TBL] [Abstract][Full Text] [Related]
16. Radiolabeled monoclonal antibody 15 and its fragments for localization and imaging of xenografts of human lung cancer.
Endo K; Kamma H; Ogata T
J Natl Cancer Inst; 1988 Aug; 80(11):835-42. PubMed ID: 3392743
[TBL] [Abstract][Full Text] [Related]
17. Different behaviour of mouse-human chimeric antibody F(ab')2 fragments of IgG1, IgG2 and IgG4 sub-class in vivo.
Buchegger F; Pèlegrin A; Hardman N; Heusser C; Lukas J; Dolci W; Mach JP
Int J Cancer; 1992 Feb; 50(3):416-22. PubMed ID: 1735611
[TBL] [Abstract][Full Text] [Related]
18. Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacy.
Behr TM; Memtsoudis S; Sharkey RM; Blumenthal RD; Dunn RM; Gratz S; Wieland E; Nebendahl K; Schmidberger H; Goldenberg DM; Becker W
Int J Cancer; 1998 Aug; 77(5):787-95. PubMed ID: 9688314
[TBL] [Abstract][Full Text] [Related]
19. Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity.
Elgqvist J; Andersson H; Bäck T; Claesson I; Hultborn R; Jensen H; Lindegren S; Olsson M; Palm S; Warnhammar E; Jacobsson L
Nucl Med Biol; 2006 Nov; 33(8):1065-72. PubMed ID: 17127181
[TBL] [Abstract][Full Text] [Related]
20. Optimizing radioimmunotherapy by matching dose distribution with tumor structure using 3D reconstructions of serial images.
Flynn AA; Pedley RB; Green AJ; Boxer GM; Boden R; Begent RH
Cancer Biother Radiopharm; 2001 Oct; 16(5):391-400. PubMed ID: 11776756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
